2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

5+

Sessions

20+

Speakers

100+

Attendees

10+

Networking Hours

The next step towards utilizing Real-World Evidence to drive Life Science and Healthcare Innovation

With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.

Learn how adoption of real-world evidence can be accelerated across pharmaceutical industry

Explore capabilities of using Artificial Intelligence & Machine Learning in taming scientific research

Understand the impact of innovative real-world evidence partnerships for better data

Adopting the Right Methodology for Real-World Evidence
Achieving New Level of Quality Insights from Data
Artificial Intelligence & Blockchain: Gamechanger in Real-World Evidence
Strategic Framework & Regulatory Considerations
Breakthrough to Excellent Data Evaluation

Real-World Evidence Methodologies
FDA’s new strategic framework for use of real-world evidence
Applications of AI & Blockchain for Real-World Data Analysis
Evaluation of data sources for better patient outcomes
Accelerating adoption of RWE in the pharmaceutical industry and across

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, from Pharmaceutical and Biopharmaceutical companies working in the following departments- Real-World Evidence | Health Economics & Outcomes Research | Market Access | Value Access | Clinical Outcomes | Clinical Development

CONFERENCE AGENDA

Registration

08:15 - 09:05

Welcome note from MarketsandMarkets

09:05 - 09:10

Opening Remarks from the Chairman

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:10 - 09:15

STRATEGIC FRAMEWORK & REGULATORY CONSIDERATIONS

Keynote Presentation: Real World Evidence - Beginning with a Considered Strategy for the Maximum Payoff

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:15 - 09:45

FDA’s Real-World Evidence Program: Framework for Evaluating RWD/ RWE for Use in Regulatory Decisions

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

09:45 - 10:15

Real-World derived Spatiotemporal Diagnosis Patterns as Descriptors for Patient Stratification and Design of Precision Medicine Solutions

Reena Gollapudy, Senior Director and Head, Health Outcomes BU, , Indegene

10:15 - 10:45

Morning Refreshments | One-to-One Networking Meetings | Networking break

10:45 - 11:35

Panel discussion: Pros & Cons of Real-World Evidence framework by FDA. Perspective from different stakeholders- providers & payers

11:35 - 12:15

Real-world evidence: How to improve your patient-centered strategy in Life Sciences?

George Mathew, Chief Medical Officer, Americas, DXC Technology

12:15 - 12:45

Economics of real-world data

Simon Dagenais, Director, Global Center of Excellence in Real-World Evidence, Vertex Pharmaceuticals

12:45 - 13:15

Lunch | One-to-One Networking Meetings | Networking break

13:15 - 14:15

ACHIEVING NEW LEVEL OF QUALITY INSIGHTS FROM DATA
Treatments for Health Conditions with High Patient Heterogeneity: Can Real World Data Make Our Drug Development Programs Smarter? Vic Spain , Senior Real World Data Scientist , Genentech	14:15 - 14:45
Virtual Research: What it Is & What it’s Doing in the Real-World Setting David Thompson, Senior Vice President, Head Of Thought Leadership, Real-World And Late Phase Research, Syneos Health	14:45 - 15:15
Afternoon Refreshments \| One-to-One Networking Meetings	15:15 - 16:10
Evaluating Strengths and Limitations of Real-World Data for Better Real-World Evidence Generation Susan Fish , Associate Director, Strategic Evidence Integration and Collaborations US Medical Affairs Hematology,, Bristol-Myers Squibb	16:10 - 16:40
Breakout Session	16:40 - 17:10
Closing remarks from the chairperson	17:10 - 17:15
Drinks Reception & Networking	17:15 - 18:15

LIFE SCIENCE ANALYTICS
Advancing Commercial Analytics through Real World Data Rachel Twardowski, Director, IBD Business Insights, Takeda Pharmaceuticals	14:15 - 14:45
Putting the Patient into Patient Journey Simon Andrews, Vice President, DRG Analytics, Decision Resources Group	14:45 - 15:15
Afternoon Refreshments \| One-to-One Networking Meetings	15:15 - 16:10
Deriving value from Real World Data with Artificial Intelligence & Machine Learning Jyotsna Kasturi , Associate Director, Real World Evidence Statistics, Teva Pharmaceuticals	16:10 - 16:40
Break out session	16:40 - 17:10
Closing remarks from the chairperson	17:10 - 17:15
Drinks Reception & Networking	17:15 - 18:15

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen	09:00 - 09:10
ADOPTION OF THE RIGHT METHODOLOGY FOR REAL-WORLD EVIDENCE
Organizational Evolution of observational research in Pharma David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA	09:10 - 09:45
Accelerating RWE through Novel Data and Site Network Access Janak Joshi, SVP & Chief Technology Officer, LifeImage	09:45 - 10:15
Use case: Impact of innovative Real-World Evidence partnerships to get better data Brian Sweet , Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb	10:15 - 10:45
Morning Refreshments \| One-to-One Networking Meetings \| Networking break	10:45 - 11:45
BREAKTHROUGH TO EXCELLENT DATA EVALUATION
Panel Discussion: Maximize the Influence of Real-World Evidence by Utilizing Available Data to Drive Life Science Innovation and Drug Development	11:45 - 12:30
Using Real World Data to Inform Early Disease Understanding Yizhou Ye, Epidemiologist, Takeda Pharmaceutical	12:30 - 13:00
Lunch \| One-to-One Networking Meetings \| Networking break	13:00 - 14:00
Demonstrating Real-World Reliability to Support Fitness-for-Use Nirosha Lederer , Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University	14:00 - 14:30
Closing remarks from the Chairman	14:30 - 14:45